CarnoSyn ® beta-alanine royalty, licensing and raw material sales revenue decreased 18% to $1.8 million during the second quarter of fiscal year 2025, as compared to $2.2 million for the second ...
However, revenue from CarnoSyn® beta-alanine declined by 18%. For the six months ending December 31, total sales rose by 14% to $67.2 million, even as the company experienced a loss of $4.2 ...
CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue decreased 18% to $1.8 million during the second quarter of fiscal year 2025, as compared to $2.2 million for the second ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback